ReviewCancers2026
Is There Geographic Variation in Poland in the Distribution of Specific High-Risk HPV Genotypes in Normal Cervical Epithelium, Dysplastic Lesions, and Cervical Cancers?
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer remains a major public health challenge worldwide and in Poland, where mortality rates are among the highest in the European Union. Persistent infection with high-risk human papillomavirus (hrHPV), particularly genotype HPV16, plays a central role in cervical carcinogenesis. This study aimed to evaluate the regional variability of hrHPV prevalence and genotype distribution in Poland and to assess its potential implications for cervical cancer incidence and prevention strategies. A systematic literature review was conducted using PubMed, Scopus, and Google Scholar to identify studies published up to May 2025 reporting hrHPV prevalence and genotypes among Polish women. Eligible studies included population-based cohorts, women undergoing screening, and patients with cervical lesions or cancer. The analysis revealed substantial heterogeneity in hrHPV prevalence and genotype distribution across regions and study populations. Nationwide data indicate high overall HPV prevalence (up to 50.9%), with HPV16 consistently dominating, followed by HPV31, HPV51, HPV52, and HPV66. Regional differences were observed, including a higher prevalence of HPV51 in southern Poland and HPV56 and HPV45 in central regions. Studies in women with abnormal cytology or cervical cancer showed markedly higher hrHPV prevalence (often >90%), with HPV16 predominating in high-grade lesions and invasive cancer. These findings confirm the dominant oncogenic role of HPV16 while highlighting significant regional variability in other hrHPV genotypes. Such differences may influence the effectiveness of screening and vaccination programs. Strengthening standardized, regionally stratified HPV surveillance is essential to optimize cervical cancer prevention and tailor public health interventions in Poland.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.